Histoindex
HistoIndex is a Singapore-based digital pathology company that combines stain-free SHG/TPEF microscopy with proprietary AI algorithms (qFibrosis, qSteatosis, qBallooning) to quantitatively assess liver fibrosis. It serves MASH pharmaceutical sponsors with clinical trial endpoint services and hepatology centers with the FibroSIGHT and FibroSIGHT Plus Laboratory Developed Tests.
- Company typePrivate
- Founded2010
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Histoindex does
HistoIndex is a Singapore-based digital pathology company, founded in 2010, that builds AI-powered imaging and analysis tools for quantitative assessment of liver fibrosis, with a primary focus on MASH (metabolic dysfunction-associated steatohepatitis) and MASLD. Its core technology combines stain-free Second Harmonic Generation (SHG) and Two-Photon Excitation Fluorescence (TPEF) microscopy—hardware embodied in the Genesis200 imaging system—with proprietary AI algorithms (qFibrosis, qSteatosis, qBallooning, qInflammation, HistoHepa, and HistoOnco HCC) that analyze over 180 collagen and tissue parameters to produce continuous, reproducible quantitative scores aligned with NASH-CRN criteria. The company has analyzed more than 10,000 patient biopsy samples from MASH clinical trials and its outputs have been embedded as secondary and exploratory endpoints in multiple FDA-facing Phase 2b/3 programs including Madrigal's MAESTRO-NASH trial for Rezdiffra, the first FDA-approved MASH treatment.
The company operates a dual business model. On the pharma services side, HistoIndex sells AI-powered digital pathology analysis as a professional service to pharmaceutical and biotech sponsors for preclinical studies, clinical research, and regulatory-grade trial endpoint quantification, with enterprise customers including Madrigal, Novartis, Akero, Sagimet, NorthSea Therapeutics, and D&D Pharmatech. On the clinical diagnostics side, the company markets Laboratory Developed Tests—FibroSIGHT (launched March 2025) and FibroSIGHT Plus (launched November 2025)—through a partner laboratory network led by PacificDX (CLIA/CAP accredited in Irvine, California) and commercial partnerships with hepatology/gastroenterology centers including Houston Research Institute and Knowledge Research Center; patient testing is insurance-coordinated with a 7-day turnaround. Go-to-market combines direct enterprise field sales for pharma with channel-partner distribution for clinical diagnostics.
Revenue streams comprise clinical testing services (insurance-reimbursed LDTs), clinical trial services (project-based), and integrated pathology services (end-to-end biopsy processing and stain-based histology bundled with AI analysis). The company is privately held, venture capital-backed by OCBC, ZIG Ventures, and SEEDS Capital following a May 2025 SGD 9 million raise, and operates with 11-50 employees from Singapore with a US operational footprint spanning Texas and California.
Histoindex firmographics
Firmographics- Name
- Histoindex
- Legal name
- Histoindex Pte Ltd.
- Website
- https://histoindex.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- HistoIndex is a Singapore-based digital pathology company that combines stain-free SHG/TPEF microscopy with proprietary AI algorithms (qFibrosis, qSteatosis, qBallooning) to quantitatively assess liver fibrosis. It serves MASH pharmaceutical sponsors with clinical trial endpoint services and hepatology centers with the FibroSIGHT and FibroSIGHT Plus Laboratory Developed Tests.
- Ownership category
- akta.pro rank
Histoindex industry classification
Industry- Product category
- AI-Powered Digital Pathology
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics) (HLAHAAAE)
- akta.pro secondary industries
- Anatomic Pathology & Histopathology (Trial Support) (HLAGAEAC), Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers) (HLAAAMAI), Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA)
Keywords
Where Histoindex is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices4 records
Markets served
Histoindex business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Clinical Testing Services: Laboratory Developed Tests (LDTs) including FibroSIGHT and FibroSIGHT Plus for clinical diagnostics of liver fibrosis in MASH patients in the US market. Testing performed at partner CLIA/CAP accredited laboratory with results returned within 7 working days.
- Clinical Trial Services: AI-powered digital pathology analysis services for pharmaceutical and biotech companies conducting MASH clinical trials. Services include preclinical studies, clinical studies, and late-stage clinical trial endpoint quantification. Used as primary, secondary, and exploratory endpoints in Phase 2b/3 trials.
- Integrated Pathology Services: End-to-end histological solutions including biopsy processing, expert pathologist review, and AI-enhanced analysis. Full suite of stain-based histology services including H&E, Masson's Trichrome, Iron, Reticulin, and specialized stains.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | One time/ perpetual license | Insurance-coordinated testing for FibroSIGHT and FibroSIGHT Plus |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels8 records
Histoindex product offering
Product offeringCore offering
HistoIndex provides AI-powered digital pathology solutions for quantitative, reproducible assessment of liver fibrosis, combining stain-free Second Harmonic Generation (SHG) and Two-Photon Excitation Fluorescence (TPEF) microscopy with proprietary AI algorithms. Its portfolio spans the Genesis200 imaging hardware, the q-Suite of AI algorithms (qFibrosis, qSteatosis, qBallooning, qInflammation), two Laboratory Developed Tests (FibroSIGHT and FibroSIGHT Plus) for clinical MASH diagnostics, and clinical trial/research services used as regulatory endpoints in MASH drug development.
Product overview
Histoindex offers a unified platform combining stain-free SHG/TPEF imaging hardware (Genesis®200), AI analysis algorithms (qFibrosis, qSteatosis, qBallooning, qInflammation, HistoHepa), and clinical diagnostic tests (FibroSIGHT, FibroSIGHT Plus). The portfolio spans preclinical research services, clinical trial support, and clinical diagnostics—enabling quantitative liver fibrosis assessment from animal studies through human clinical practice. The q-Suite provides comprehensive MASH histology quantification, while FibroSIGHT products bring AI-powered analysis into clinical care via CLIA/CAP accredited laboratory services.
Differentiator
Problem solved
Functional benefit
Brands
- FibroSIGHT: Laboratory Developed Test designed to aid pathologists with reliable detection and visualization of liver fibrosis in MASH patients using proprietary stain-free imaging technology
- FibroSIGHT Plus
- qFibrosis
- qSteatosis
- qBallooning
- qInflammation
- HistoOnco HCC
- Genesis200 Imaging System
- HistoHepa AI
Products and services
- Genesis®200 Imaging System Laser-based imaging system that uses label-free Second Harmonic Generation (SHG) and Two-Photon Excitation Fluorescence (TPEF) microscopy to visualize fibrillar collagen and cellular architecture in unstained tissue biopsies at high resolution. Sold to research and pharmaceutical partners as part of the digital pathology platform.
- qFibrosis® Automated, quantitative AI algorithm for liver fibrosis assessment using SHG/TPEF microscopy. Analyzes over 180 collagen parameters (fiber count, length, width, cross-linkages, spatial distribution) and outputs continuous fibrosis scores aligned with NASH-CRN stages. Used as a primary, secondary, or exploratory endpoint in MASH clinical trials and as the analytical engine for FibroSIGHT Plus.
- qSteatosis® AI-based digital pathology algorithm providing objective, quantitative measurement of hepatic fat accumulation (steatosis) in liver biopsy samples using SHG/TPEF imaging of unstained tissue. Generates continuous qSteatosis values mapped to ordinal grades (qS0-qS3) aligned with NASH-CRN scoring.
- qBallooning® AI-driven algorithm that identifies and quantifies ballooned hepatocytes, a key histological feature of MASH, using SHG/TPEF image analysis. Generates continuous ballooning values converted to grades (qB0-qB2).
- qInflammation® Algorithm for detecting and quantifying portal and lobular inflammation in H&E stained liver tissue digital images using AI image analysis, providing objective metrics for inflammatory cell infiltration and distribution.
- HistoOnco™ HCC AI-based algorithm for objective, quantitative assessment of fibrosis in hepatocellular carcinoma (HCC) using stain-free SHG/TPEF imaging. Evaluates fibrosis separately within tumor and non-tumor regions and integrates features into prognostic indices predicting recurrence-free survival (RFS) and overall survival (OS).
- FibroSIGHT™ HistoIndex's first Laboratory Developed Test (LDT) for clinical diagnostics of liver fibrosis in MASH patients, available in the US. Uses proprietary stain-free SHG imaging to provide reliable and consistent visualization of collagen fibers in unstained biopsy samples, integrating into existing pathologist workflows. Testing is performed at the CLIA/CAP accredited PacificDX laboratory in Irvine, California, with results returned within 7 working days.
- FibroSIGHT™ Plus Advanced Laboratory Developed Test (LDT) featuring AI-based quantitative analysis using the qFibrosis algorithm. Provides automated, objective, continuous-scale measurements of liver fibrosis severity in MASH patients, with qFibrosis values mapped to NASH-CRN stages and risk classifications. Performs at AUROC 0.88 for at-risk fibrosis (F2-F4) with 85% sensitivity and 71% specificity, and AUROC 0.91 with 96% specificity for cirrhosis (F4).
- Integrated Services End-to-end histological service combining biopsy processing, expert histopathological evaluation, stain-based histology (H&E, Masson's Trichrome, Iron, Reticulin, Ubiquitin, Copper, CK7), and AI-enhanced analysis via FibroSIGHT/FibroSIGHT Plus. Performed at the PacificDX CLIA/CAP accredited laboratory in Irvine, California.
- Research-Based Services AI-powered digital pathology service supporting preclinical studies, clinical research, and clinical trials. Includes stain-free imaging, quantitative analysis of fibrosis, steatosis, ballooning, and inflammation, zonal localization analysis, and regulatory-grade endpoints (primary, secondary, exploratory) for Phase 2b/3 MASH trials and translational research.
Quantifiable outcome
- AUROC 0.88 for detecting at-risk fibrosis (F2-F4) with 85% sensitivity and 71% specificity
- +4 more outcomes
Companies that use Histoindex
Customer profileNamed customers9 records
Segments4 records
Ideal customer profiles4 records
Histoindex technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature9 records
Histoindex partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered key and core.
- D&D PharmatechkeyClinical trial partnership for AI-powered analysis of liver biopsy samples from Phase 2 trial of zabopegdutide (DD01). HistoIndex's qFibrosis tool demonstrated 81.8% fibrosis improvement vs 18.8% placebo, corroborating and extending blinded pathologist results for the investigational MASH treatment.
- Knowledge Research CentercoreCommercial partnership with KRC in Orange, California expanding access to MASH diagnostic services on the US West Coast. The collaboration enhances liver disease diagnostics and workflow efficiency in hepatology and gastroenterology centers, strengthening HistoIndex's growing network across both US East and West Coasts.
- Houston Research InstitutecoreStrategic partnership providing all four HRI medical centers in Houston access to HistoIndex's integrated diagnostic offering combining expert histopathological evaluation with AI-based FibroSIGHT Plus test for quantitative assessment of liver fibrosis. The collaboration integrates traditional pathology methods with AI-based analysis to enhance diagnostic capabilities and support informed clinical decision-making across hepatology and gastroenterology practices.
- PacificDXcoreCLIA/CAP accredited partner laboratory in Irvine, California performing FibroSIGHT and FibroSIGHT Plus testing services. PacificDX handles full biopsy processing including receiving samples, preparing FFPE blocks, and tissue slide preparation. The partnership enables end-to-end histological services from sample processing to expert AI-enhanced analysis.
- Madrigal PharmaceuticalskeyLong-standing partnership contributing qFibrosis analysis to MAESTRO-NASH Phase 3 trial for Rezdiffra (resmetirom), the first FDA-approved MASH treatment. HistoIndex's exploratory analyses helped identify F3 patients as best responders and influenced Phase 3 trial design including patient stratification and duration.
- Akero TherapeuticskeyProvided AI-assisted digital pathology analysis for Phase 2b SYMMETRY and HARMONY trials of efruxifermin, corroborating fibrosis improvements and demonstrating consistent reduction in total fibrosis and septa area.
- Sagimet BioscienceskeyqFibrosis incorporated as secondary and exploratory efficacy endpoints in FASCINATE-2 Phase 2b trial for denifanstat, validating treatment effects with significant fibrosis improvement (p=0.002).
- NorthSea TherapeuticskeyProvided qFibrosis analysis for ICONA Phase 2b trial of icosabutate, revealing synergistic dose response in fibrosis stage regression with significant treatment effects in Type 2 Diabetes patients.
- NovartiskeyDigital pathology analysis for TANDEM and FLIGHT-FXR trials of tropifexor, where qFibrosis detected treatment effects undetected by standard assessments, demonstrating additive efficacy in combination therapy.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Histoindex competitors and assessment
Company assessmentDirect peers
- PathAI: AI-powered digital pathology platform serving pharma clinical trials and diagnostic workflows. Direct competitor in AI pathology for clinical trial endpoints and tissue-based diagnostics, though broader across indications than HistoIndex.
- Owkin: AI pathology company building histology-based biomarkers for pharma R&D and diagnostics. Competes with HistoIndex in AI-driven pathology endpoints for clinical trials, though with broader oncology focus.
- Perspectum: Liver diagnostics company using MRI-based multiparametric imaging (LiverMultiScan) for non-invasive liver assessment. Competes for MASH diagnostic slots that FibroSIGHT targets.
- Echosens: Maker of FibroScan, the leading non-invasive liver stiffness assessment tool. Competes with FibroSIGHT for MASH patient stratification, though via elastography rather than biopsy-based AI.
Emerging players
- Ibex Medical Analytics: AI-based cancer diagnostics platform with clinical-grade algorithms for pathology. Partial overlap in AI tissue analysis for diagnostics, though primarily oncology-focused.
- Proscia: Digital pathology platform combining AI image analysis with enterprise workflow software. Competes in the broader pathology AI infrastructure layer where HistoIndex's q-Suite operates.
- Aignostics: AI digital pathology company focused on biomarker discovery and clinical trial support for pharma. Overlaps with HistoIndex's research-based services and clinical trial endpoint offerings.
- Indica Labs: Provider of AI-powered digital pathology image analysis software (HALO) widely used in pharma research and clinical trials. Comparable technology layer to HistoIndex's qFibrosis algorithm suite.
Broad incumbents
- Akoya Biosciences: Spatial biology company offering multiplexed tissue imaging and analysis for pharma and research. Adjacent in tissue-based biomarker quantification though focused on spatial-omics rather than SHG-based fibrosis quantification.
Regional players
- Resonance Health: Provider of MRI-based liver fat and iron quantification (FerriScan, HepaFat-Scan). Competes in non-invasive liver disease assessment though primarily serving Australian/Asian markets with MRI rather than biopsy-based approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Histoindex social profiles
Digital presenceHistoindex compliance and trust
Trust signalCompliance2 records
Histoindex financial estimates
Financial estimateRevenue estimate
Valuation estimate
Histoindex leadership team
Management profileNumber of profiles
Profiles3 records
Histoindex funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Histoindex M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Histoindex
What does Histoindex do?
HistoIndex provides AI-powered digital pathology solutions for quantitative, reproducible assessment of liver fibrosis, combining stain-free Second Harmonic Generation (SHG) and Two-Photon Excitation Fluorescence (TPEF) microscopy with proprietary AI algorithms. Its portfolio spans the Genesis200 imaging hardware, the q-Suite of AI algorithms (qFibrosis, qSteatosis, qBallooning, qInflammation), two Laboratory Developed Tests (FibroSIGHT and FibroSIGHT Plus) for clinical MASH diagnostics, and clinical trial/research services used as regulatory endpoints in MASH drug development.
Is Histoindex a public or private company?
Histoindex is a private company. It is classified as venture growth investor backed and is currently operating.
When was Histoindex founded?
Histoindex was founded in 2010. It employs 11 to 50 people.
Where is Histoindex based?
Histoindex is headquartered in Singapore, Singapore, in the Asia region.
How does Histoindex make money?
Three revenue lines are on record. Clinical Testing Services are the primary driver. The others are clinical Trial Services and integrated Pathology Services.
Who are Histoindex's main competitors?
Direct peers on record are PathAI, Owkin, Perspectum and Echosens. Emerging players are Ibex Medical Analytics, Proscia, Aignostics and Indica Labs. Akoya Biosciences is listed as a broad incumbent. Resonance Health is listed as a regional player.
Does Histoindex have an API?
No public API is recorded for Histoindex.
What industry is Histoindex in?
Histoindex's product category is AI-Powered Digital Pathology. Its primary akta.pro industry code is HLAHAAAE, Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics), with a secondary code of HLAGAEAC, Anatomic Pathology & Histopathology (Trial Support). Its NAICS code is 621511 and its SIC code is 2835.